MedTrace Logo

Letermovir for R+ Study

NCT07706166 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2026-07-15

No results posted yet for this study

Summary

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.

Participants will take letermovir for 84 days.

Conditions

  • Kidney Transplant
  • Liver Transplant

Interventions

DRUG

Letermovir

1 tablet by mouth, once daily, for 84 days

Sponsors & Collaborators

Principal Investigators

  • David Al-Adra, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706166 on ClinicalTrials.gov